These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36091770)

  • 1. Efficacy and safety of targeted therapeutics for patients with radioiodine-refractory differentiated thyroid cancer: Systematic review and network meta-analysis.
    Ji X; Liang W; Lv G; Ding C; Lai H; Li L; Zeng Q; Lv B; Sheng L
    Front Pharmacol; 2022; 13():933648. PubMed ID: 36091770
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.
    Jing R; Wu N; Wu Y; Zhang Q; Liang Q; Huang P; Yi S
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2658-2672. PubMed ID: 38970485
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine kinase inhibitors for radioiodine refractory differentiated thyroid cancer: A systematic review and meta-analysis.
    Yu J; Liu Z; Su Y; Peng X; Xie Y
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):379-388. PubMed ID: 38351437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of targeted therapy for radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
    Zhang Y; Zhang X; Lin L; Xing M
    J Clin Endocrinol Metab; 2024 Sep; ():. PubMed ID: 39292866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
    Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
    Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
    Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
    Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeted therapies for previously treated advanced or metastatic renal cell carcinoma: systematic review and network meta-analysis.
    Karner C; Kew K; Wakefield V; Masento N; Edwards SJ
    BMJ Open; 2019 Mar; 9(3):e024691. PubMed ID: 30826762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
    Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
    JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma.
    Du W; Shi X; Fang Q; Zhang X; Liu S
    Front Endocrinol (Lausanne); 2022; 13():768028. PubMed ID: 35282451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
    Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
    BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular Endothelial Growth Factor Receptor Inhibitors in Chinese Patients With Advanced Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Network Meta-Analysis and Cost-Effectiveness Analysis.
    Zhu Y; Liu K; Wang K; Peng L
    Front Endocrinol (Lausanne); 2022; 13():909333. PubMed ID: 35909569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial or salvage treatment with apatinib shows promise against radioiodine-refractory differentiated thyroid carcinoma.
    Qiu X; Cheng L; Sa R; Fu H; Jin Y; Chen L
    Eur Thyroid J; 2022 Feb; 11(2):. PubMed ID: 35060924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
    Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L
    Crit Rev Oncol Hematol; 2024 Dec; 204():104522. PubMed ID: 39332750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
    PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer.
    Koehler VF; Berg E; Adam P; Weber GL; Pfestroff A; Luster M; Kutsch JM; Lapa C; Sandner B; Rayes N; Fuss CT; Kreissl MC; Hoster E; Allelein S; Schott M; Todica A; Fassnacht M; Kroiss M; Spitzweg C
    Thyroid; 2021 Oct; 31(10):1531-1541. PubMed ID: 34405734
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of third-line treatments for advanced gastric cancer: A systematic review and network meta-analysis.
    Zhang C; Xiang Y; Wang J; Yan D
    Front Oncol; 2023; 13():1118820. PubMed ID: 36937403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
    Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.